Literature DB >> 33807899

The CXCL2/IL8/CXCR2 Pathway Is Relevant for Brain Tumor Malignancy and Endothelial Cell Function.

Ruth M Urbantat1, Anne Blank1, Irina Kremenetskaia1, Peter Vajkoczy1,2, Güliz Acker1,2,3, Susan Brandenburg1.   

Abstract

We aimed to evaluate the angiogenic capacity of CXCL2 and IL8 affecting human endothelial cells to clarify their potential role in glioblastoma (GBM) angiogenesis. Human GBM samples and controls were stained for proangiogenic factors. Survival curves and molecule correlations were obtained from the TCGA (The Cancer Genome Atlas) database. Moreover, proliferative, migratory and angiogenic activity of peripheral (HUVEC) and brain specific (HBMEC) primary human endothelial cells were investigated including blockage of CXCR2 signaling with SB225502. Gene expression analyses of angiogenic molecules from endothelial cells were performed. Overexpression of VEGF and CXCL2 was observed in GBM patients and associated with a survival disadvantage. Molecules of the VEGF pathway correlated but no relation for CXCR1/2 and CXCL2/IL8 was found. Interestingly, receptors of endothelial cells were not induced by addition of proangiogenic factors in vitro. Proliferation and migration of HUVEC were increased by VEGF, CXCL2 as well as IL8. Their sprouting was enhanced through VEGF and CXCL2, while IL8 showed no effect. In contrast, brain endothelial cells reacted to all proangiogenic molecules. Additionally, treatment with a CXCR2 antagonist led to reduced chemokinesis and sprouting of endothelial cells. We demonstrate the impact of CXCR2 signaling on endothelial cells supporting an impact of this pathway in angiogenesis of glioblastoma.

Entities:  

Keywords:  HBMEC; SB225002; chemokines; glioblastoma; tumor angiogenesis

Mesh:

Substances:

Year:  2021        PMID: 33807899      PMCID: PMC7961945          DOI: 10.3390/ijms22052634

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  68 in total

Review 1.  Angiogenesis assays: problems and pitfalls.

Authors:  R Auerbach; N Akhtar; R L Lewis; B L Shinners
Journal:  Cancer Metastasis Rev       Date:  2000       Impact factor: 9.264

Review 2.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  The chemokine receptor CXCR2 is differentially regulated on glial cells in vivo but is not required for successful remyelination after cuprizone-induced demyelination.

Authors:  Maren Lindner; Corinna Trebst; Sandra Heine; Thomas Skripuletz; Paraskevi N Koutsoudaki; Martin Stangel
Journal:  Glia       Date:  2008-08-01       Impact factor: 7.452

4.  Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.

Authors:  N O Schmidt; M Westphal; C Hagel; S Ergün; D Stavrou; E M Rosen; K Lamszus
Journal:  Int J Cancer       Date:  1999-02-19       Impact factor: 7.396

5.  Molecular mechanisms of the antitumor activity of SB225002: a novel microtubule inhibitor.

Authors:  Ahmed E Goda; Makoto Koyama; Yoshihiro Sowa; Khaled M Elokely; Tatsushi Yoshida; Bo-Yeon Kim; Toshiyuki Sakai
Journal:  Biochem Pharmacol       Date:  2013-04-20       Impact factor: 5.858

Review 6.  Cancer CXC chemokine networks and tumour angiogenesis.

Authors:  Robert M Strieter; Marie D Burdick; Javier Mestas; Brigitte Gomperts; Michael P Keane; John A Belperio
Journal:  Eur J Cancer       Date:  2006-02-28       Impact factor: 9.162

7.  Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-8(77)).

Authors:  M Tada; K Suzuki; Y Yamakawa; Y Sawamura; S Sakuma; H Abe; E van Meir; N de Tribolet
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

Review 8.  Modes of resistance to anti-angiogenic therapy.

Authors:  Gabriele Bergers; Douglas Hanahan
Journal:  Nat Rev Cancer       Date:  2008-08       Impact factor: 60.716

Review 9.  Tumor refractoriness to anti-VEGF therapy.

Authors:  Domenico Ribatti
Journal:  Oncotarget       Date:  2016-07-19

10.  IL-8/CXCR1/2 signalling promotes tumor cell proliferation, invasion and vascular mimicry in glioblastoma.

Authors:  Ira Sharma; Avninder Singh; Fouzia Siraj; Sunita Saxena
Journal:  J Biomed Sci       Date:  2018-08-08       Impact factor: 8.410

View more
  5 in total

Review 1.  Bone metastasis from glioblastoma: a systematic review.

Authors:  Michael J Strong; Sravanthi Koduri; Jodi A Allison; Cecilia M Pesavento; Sebele Ogunsola; Oludotun Ogunsola; Timothy J Yee; Siri Sahib S Khalsa; Yamaan S Saadeh; Jacob R Joseph; Osama N Kashlan; Paul Park; Mark E Oppenlander; Nicholas J Szerlip
Journal:  J Neurooncol       Date:  2022-05-17       Impact factor: 4.130

Review 2.  Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy.

Authors:  Zhi-Jian Han; Yang-Bing Li; Lu-Xi Yang; Hui-Juan Cheng; Xin Liu; Hao Chen
Journal:  Molecules       Date:  2021-12-27       Impact factor: 4.411

3.  Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.

Authors:  Ruth M Urbantat; Claudius Jelgersma; Susan Brandenburg; Melina Nieminen-Kelhä; Irina Kremenetskaia; Julia Zollfrank; Susanne Mueller; Kerstin Rubarth; Arend Koch; Peter Vajkoczy; Gueliz Acker
Journal:  Int J Mol Sci       Date:  2021-10-16       Impact factor: 5.923

4.  Combining TMZ and SB225002 induces changes of CXCR2 and VEGFR signalling in primary human endothelial cells in vitro.

Authors:  Susan Brandenburg; Gueliz Acker; Ruth M Urbantat; Claudius Jelgersma; Peter Vajkoczy
Journal:  Oncol Rep       Date:  2022-07-20       Impact factor: 4.136

Review 5.  Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk.

Authors:  Khadijeh Barzaman; Rana Vafaei; Mitra Samadi; Mohammad Hossein Kazemi; Aysooda Hosseinzadeh; Parnaz Merikhian; Shima Moradi-Kalbolandi; Mohammad Reza Eisavand; Houra Dinvari; Leila Farahmand
Journal:  Cancer Cell Int       Date:  2022-08-19       Impact factor: 6.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.